These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11048889)

  • 21. Visceral adipose tissue accumulation, secretory phospholipase A2-IIA and atherogenecity of LDL.
    Paradis ME; Hogue MO; Mauger JF; Couillard C; Couture P; Bergeron N; Lamarche B
    Int J Obes (Lond); 2006 Nov; 30(11):1615-22. PubMed ID: 16534517
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of group II secretory phospholipase A2 in atherosclerosis: 2. Potential involvement of biologically active oxidized phospholipids.
    Leitinger N; Watson AD; Hama SY; Ivandic B; Qiao JH; Huber J; Faull KF; Grass DS; Navab M; Fogelman AM; de Beer FC; Lusis AJ; Berliner JA
    Arterioscler Thromb Vasc Biol; 1999 May; 19(5):1291-8. PubMed ID: 10323782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2.
    Ivandic B; Castellani LW; Wang XP; Qiao JH; Mehrabian M; Navab M; Fogelman AM; Grass DS; Swanson ME; de Beer MC; de Beer F; Lusis AJ
    Arterioscler Thromb Vasc Biol; 1999 May; 19(5):1284-90. PubMed ID: 10323781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inter-relationships between small, dense low-density lipoprotein (LDL), plasma triacylglycerol and LDL apoprotein B in an atherogenic lipoprotein phenotype in free-living subjects.
    Griffin BA; Minihane AM; Furlonger N; Chapman C; Murphy M; Williams D; Wright JJ; Williams CM
    Clin Sci (Lond); 1999 Sep; 97(3):269-76. PubMed ID: 10464051
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Atherogenic role of lysophosphatidylcholine in low-density lipoprotein modified by phospholipase A2 and in diabetic patients: protection by nitric oxide donor.
    Sonoki K; Iwase M; Iino K; Ichikawa K; Ohdo S; Higuchi S; Yoshinari M; Iida M
    Metabolism; 2003 Mar; 52(3):308-14. PubMed ID: 12647268
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phospholipase A(2) in vascular disease.
    Hurt-Camejo E; Camejo G; Peilot H; Oörni K; Kovanen P
    Circ Res; 2001 Aug; 89(4):298-304. PubMed ID: 11509445
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B.
    Chait A; Brazg RL; Tribble DL; Krauss RM
    Am J Med; 1993 Apr; 94(4):350-6. PubMed ID: 8475928
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lipolytic modification of LDL by phospholipase A2 induces particle aggregation in the absence and fusion in the presence of heparin.
    Hakala JK; Oörni K; Ala-Korpela M; Kovanen PT
    Arterioscler Thromb Vasc Biol; 1999 May; 19(5):1276-83. PubMed ID: 10323780
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of apo B lipoproteins with arterial proteoglycans: pathological significance and molecular basis.
    Camejo G; Hurt-Camejo E; Wiklund O; Bondjers G
    Atherosclerosis; 1998 Aug; 139(2):205-22. PubMed ID: 9712326
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proteolysis sensitizes LDL particles to phospholipolysis by secretory phospholipase A2 group V and secretory sphingomyelinase.
    Plihtari R; Hurt-Camejo E; Oörni K; Kovanen PT
    J Lipid Res; 2010 Jul; 51(7):1801-9. PubMed ID: 20124257
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiotensin II type 1-receptor antagonism prevents type IIA secretory phospholipase A2-dependent lipid peroxidation.
    Luchtefeld M; Bandlow N; Tietge UJ; Grote K; Pfeilschifter J; Kaszkin M; Beck S; Drexler H; Schieffer B
    Atherosclerosis; 2007 Sep; 194(1):62-70. PubMed ID: 17069818
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes.
    Pontrelli L; Parris W; Adeli K; Cheung RC
    Metabolism; 2002 Mar; 51(3):334-42. PubMed ID: 11887170
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of triglyceride-rich lipoproteins-related markers and low-density lipoprotein heterogeneity with cardiovascular risk: effectiveness of polyacrylamide-gel electrophoresis as a method of determining low-density lipoprotein particle size.
    Tani S; Matsumoto M; Nagao K; Hirayama A
    J Cardiol; 2014 Jan; 63(1):60-8. PubMed ID: 24016623
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites: a potential mechanism for increased atherogenicity.
    Galeano NF; Al-Haideri M; Keyserman F; Rumsey SC; Deckelbaum RJ
    J Lipid Res; 1998 Jun; 39(6):1263-73. PubMed ID: 9643358
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phospholipase A2 type II binds to extracellular matrix biglycan: modulation of its activity on LDL by colocalization in glycosaminoglycan matrixes.
    Sartipy P; Bondjers G; Hurt-Camejo E
    Arterioscler Thromb Vasc Biol; 1998 Dec; 18(12):1934-41. PubMed ID: 9848887
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Women have a larger and less atherogenic low density lipoprotein particle size than men.
    Nikkilä M; Pitkäjärvi T; Koivula T; Solakivi T; Lehtimäki T; Laippala P; Jokela H; Lehtomäki E; Seppä K; Sillanaukee P
    Atherosclerosis; 1996 Jan; 119(2):181-90. PubMed ID: 8808495
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dynamics of dense electronegative low density lipoproteins and their preferential association with lipoprotein phospholipase A(2).
    Gaubatz JW; Gillard BK; Massey JB; Hoogeveen RC; Huang M; Lloyd EE; Raya JL; Yang CY; Pownall HJ
    J Lipid Res; 2007 Feb; 48(2):348-57. PubMed ID: 17102149
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Apolipoprotein B-100 conformation and particle surface charge in human LDL subspecies: implication for LDL receptor interaction.
    Lund-Katz S; Laplaud PM; Phillips MC; Chapman MJ
    Biochemistry; 1998 Sep; 37(37):12867-74. PubMed ID: 9737865
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of a low-calorie diet associated with weight loss on lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in healthy obese women.
    Tzotzas T; Filippatos TD; Triantos A; Bruckert E; Tselepis AD; Kiortsis DN
    Nutr Metab Cardiovasc Dis; 2008 Sep; 18(7):477-82. PubMed ID: 17928209
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Atherogenicity of low-density lipoproteins (LDL). A problem of quantity or quality?].
    Dejager S; Turpin G
    Presse Med; 1995 Dec; 24(38):1772-6. PubMed ID: 8545426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.